-
Brana, I., Pham, N. A., Kim, L. et al.
Novel combinations of PI3K-mTOR inhibitors
with dacomitinib or chemotherapy in
PTEN-deficient patient-derived tumor
xenografts.
Oncotarget 8, 84659,
doi:10.18632/oncotarget.19109 (2017).
-
Chang, Q., Jurisica, I., Do, T. et al.
Hypoxia predicts aggressive growth and
spontaneous metastasis formation from
orthotopically grown primary xenografts of
human pancreatic cancer.
Cancer Res 71, 3110,
doi:10.1158/0008-5472.CAN-10-4049 (2011).
-
Chia, P. L., Parakh, S., Tsao, M. S. et al.
Targeting and Efficacy of Novel
mAb806-Antibody-Drug Conjugates in Malignant
Mesothelioma.
Pharmaceuticals (Basel) 13,
doi:10.3390/ph13100289 (2020).
-
Cybulska, P., Stewart, J. M., Sayad, A. et al.
A Genomically Characterized Collection of
High-Grade Serous Ovarian Cancer Xenografts
for Preclinical Testing.
Am J Pathol 188, 1120,
doi:10.1016/j.ajpath.2018.01.019 (2018).
-
Derouet, M. F., Allen, J., Wilson, G. W. et al.
Towards personalized induction therapy for
esophageal adenocarcinoma: organoids derived
from endoscopic biopsy recapitulate the
pre-treatment tumor.
Sci Rep 10, 14514,
doi:10.1038/s41598-020-71589-4 (2020).
-
Dodbiba, L., Teichman, J., Fleet, A. et al.
Primary esophageal and gastro-esophageal
junction cancer xenograft models:
clinicopathological features and
engraftment.
Lab Invest 93, 397,
doi:10.1038/labinvest.2013.8 (2013).
-
Gao, S., Soares, F., Wang, S. et al.
CRISPR screens identify cholesterol
biosynthesis as a therapeutic target on
stemness and drug resistance of colon
cancer.
Oncogene 40, 6601,
doi:10.1038/s41388-021-01882-7 (2021).
-
Gebregiworgis, T., Marshall, C. B., Nishikawa,
T. et al.
Multiplexed Real-Time NMR GTPase Assay for
Simultaneous Monitoring of Multiple Guanine
Nucleotide Exchange Factor Activities from
Human Cancer Cells and Organoids.
Journal of the American Chemical Society
140, 4473, doi:10.1021/jacs.7b13703 (2018).
-
Gebregiworgis, T., Kano, Y., St-Germain, J. et
al.
The Q61H mutation decouples KRAS from
upstream regulation and renders cancer cells
resistant to SHP2 inhibitors.
Nat Commun 12, 6274,
doi:10.1038/s41467-021-26526-y (2021).
-
Gendoo, D. M. A., Denroche, R. E., Zhang, A. et
al.
Whole genomes define concordance of matched
primary, xenograft, and organoid models of
pancreas cancer.
PLoS Comput Biol 15, e1006596,
doi:10.1371/journal.pcbi.1006596 (2019).
-
Grunwald, B. T., Devisme, A., Andrieux, G. et
al.
Spatially confined sub-tumor
microenvironments in pancreatic
cancer.
Cell 184, 5577,
doi:10.1016/j.cell.2021.09.022 (2021).
-
Hai, J., Sakashita, S., Allo, G. et al.
Inhibiting MDM2-p53 Interaction Suppresses
Tumor Growth in Patient-Derived Non-Small
Cell Lung Cancer Xenograft Models.
J Thorac Oncol 10, 1172,
doi:10.1097/JTO.0000000000000584 (2015).
-
Hai, J., Liu, S., Bufe, L. et al.
Synergy of WEE1 and mTOR Inhibition in
Mutant KRAS-Driven Lung Cancers.
Clin Cancer Res 23, 6993,
doi:10.1158/1078-0432.CCR-17-1098 (2017).
-
Haynes, J., McKee, T. D., Haller, A. et al.
Administration of Hypoxia-Activated Prodrug
Evofosfamide after Conventional Adjuvant
Therapy Enhances Therapeutic Outcome and
Targets Cancer-Initiating Cells in
Preclinical Models of Colorectal
Cancer.
Clin Cancer Res 24, 2116,
doi:10.1158/1078-0432.CCR-17-1715 (2018).
-
Huo, K. G., D'Arcangelo, E. & Tsao, M. S.
Patient-derived cell line, xenograft and
organoid models in lung cancer
therapy.
Transl Lung Cancer Res 9, 2214,
doi:10.21037/tlcr-20-154 (2020).
-
Huo, K. G., Notsuda, H., Fang, Z. et al.
Lung Cancer Driven by BRAF(G469V) Mutation
Is Targetable by EGFR Kinase
Inhibitors.
J Thorac Oncol 17, 277,
doi:10.1016/j.jtho.2021.09.008 (2022).
-
Hussain, A., Voisin, V., Poon, S. et al.
Distinct fibroblast functional states drive
clinical outcomes in ovarian cancer and are
regulated by TCF21.
J Exp Med 217,
doi:10.1084/jem.20191094 (2020).
-
John, T., Kohler, D., Pintilie, M. et al.
The ability to form primary tumor xenografts
is predictive of increased risk of disease
recurrence in early-stage non-small cell lung
cancer.
Clin Cancer Res 17, 134,
doi:10.1158/1078-0432.CCR-10-2224 (2011).
-
John, T., Yanagawa, N., Kohler, D. et al.
Characterization of lymphomas developing in
immunodeficient mice implanted with primary
human non-small cell lung cancer.
J Thorac Oncol 7, 1101,
doi:10.1097/JTO.0b013e3182519d4d (2012).
-
Kano, Y., Gebregiworgis, T., Marshall, C. B. et
al.
Tyrosyl phosphorylation of KRAS stalls
GTPase cycle via alteration of switch I and
II conformation.
Nat Commun 10, 224,
doi:10.1038/s41467-018-08115-8 (2019).
-
Karamboulas, C., Bruce, J. P., Hope, A. J. et
al.
Patient-Derived Xenografts for
Prognostication and Personalized Treatment
for Head and Neck Squamous Cell
Carcinoma.
Cell Rep 25, 1318,
doi:10.1016/j.celrep.2018.10.004 (2018).
-
Karamboulas, C. & Ailles, L.
Patient-derived xenografts: a promising
resource for preclinical cancer
research.
Mol Cell Oncol 6, 1558684,
doi:10.1080/23723556.2018.1558684 (2019).
-
Koshkin, V., De Oliveira, M. B., Peng, C. et
al.
Multi-drug-resistance efflux in
cisplatin-naive and cisplatin-exposed A2780
ovarian cancer cells responds differently to
cell culture dimensionality.
Mol Clin Oncol 15, 161,
doi:10.3892/mco.2021.2323 (2021).
-
Ku, A., Chan, C., Aghevlian, S. et al.
MicroSPECT/CT Imaging of Cell-Line and
Patient-Derived EGFR-Positive Tumor
Xenografts in Mice with Panitumumab Fab
Modified with Hexahistidine Peptides To
Enable Labeling with (99m)Tc(I) Tricarbonyl
Complex.
Mol Pharm 16, 3559,
doi:10.1021/acs.molpharmaceut.9b00422 (2019).
-
Lai Benjamin, F. L., Lu Rick, X., Hu, Y. et al.
Recapitulating pancreatic tumor
microenvironment through synergistic use of
patient organoids and organ-on-a-chip
vasculature.
Adv Funct Mater 30,
doi:10.1002/adfm.202000545 (2020).
-
Li, L., Wei, Y., To, C. et al.
Integrated omic analysis of lung cancer
reveals metabolism proteome signatures with
prognostic impact.
Nat Commun 5, 5469,
doi:10.1038/ncomms6469 (2014).
-
Lima-Fernandes, E., Murison, A., da Silva
Medina, T. et al.
Targeting bivalency de-represses Indian
Hedgehog and inhibits self-renewal of
colorectal cancer-initiating cells.
Nat Commun 10, 1436,
doi:10.1038/s41467-019-09309-4 (2019).
-
Lohse, I., Lourenco, C., Ibrahimov, E. et al.
Assessment of hypoxia in the stroma of
patient-derived pancreatic tumor
xenografts.
Cancers (Basel) 6, 459,
doi:10.3390/cancers6010459 (2014).
-
Lohse, I., Kumareswaran, R., Cao, P. et al.
Effects of Combined Treatment with Ionizing
Radiation and the PARP Inhibitor Olaparib in
BRCA Mutant and Wild Type Patient-Derived
Pancreatic Cancer Xenografts.
PLoS One 11, e0167272,
doi:10.1371/journal.pone.0167272 (2016).
-
Lohse, I., Rasowski, J., Cao, P. et al.
Targeting hypoxic microenvironment of
pancreatic xenografts with the
hypoxia-activated prodrug TH-302.
Oncotarget 7, 33571,
doi:10.18632/oncotarget.9654 (2016).
-
Martin, P., Stewart, E., Pham, N. A. et al.
Cetuximab Inhibits T790M-Mediated Resistance
to Epidermal Growth Factor Receptor Tyrosine
Kinase Inhibitor in a Lung Adenocarcinoma
Patient-Derived Xenograft Mouse
Model.
Clin Lung Cancer 17, 375,
doi:10.1016/j.cllc.2016.01.002 (2016).
-
Martins-Filho, S. N., Weiss, J., Pham, N. A. et
al.
EGFR-mutated lung adenocarcinomas from
patients who progressed on EGFR-inhibitors
show high engraftment rates in xenograft
models.
Lung Cancer 145, 144,
doi:10.1016/j.lungcan.2020.03.022 (2020).
-
Mason, J. M., Lin, D. C., Wei, X. et al.
Functional characterization of CFI-400945, a
Polo-like kinase 4 inhibitor, as a potential
anticancer agent.
Cancer Cell 26, 163,
doi:10.1016/j.ccr.2014.05.006 (2014).
-
Mer, A. S., Ba-Alawi, W., Smirnov, P. et al.
Integrative Pharmacogenomics Analysis of
Patient-Derived Xenografts.
Cancer Res 79, 4539,
doi:10.1158/0008-5472.CAN-19-0349 (2019).
-
Mirhadi, S., Tam, S., Li, Q. et al.
Integrative analysis of non-small cell lung
cancer patient-derived xenografts identifies
distinct proteotypes associated with patient
outcomes.
Nat Commun 13, 1811,
doi:10.1038/s41467-022-29444-9 (2022).
-
Murillo-Sauca, O., Chung, M. K., Shin, J. H. et
al.
CD271 is a functional and targetable marker
of tumor-initiating cells in head and neck
squamous cell carcinoma.
Oncotarget 5, 6854,
doi:10.18632/oncotarget.2269 (2014).
-
Nakajima, T., Geddie, W., Anayama, T. et al.
Patient-derived tumor xenograft models
established from samples obtained by
endobronchial ultrasound-guided
transbronchial needle aspiration.
Lung Cancer 89, 110,
doi:10.1016/j.lungcan.2015.05.018 (2015).
-
Notta, F., Chan-Seng-Yue, M., Lemire, M. et al.
A renewed model of pancreatic cancer
evolution based on genomic rearrangement
patterns.
Nature 538, 378,
doi:10.1038/nature19823 (2016).
-
O'Brien, C. A., Pollett, A., Gallinger, S. et
al.
A human colon cancer cell capable of
initiating tumour growth in immunodeficient
mice.
Nature 445, 106,
doi:10.1038/nature05372 (2007).
-
O'Brien, C. A., Kreso, A., Ryan, P. et al.
ID1 and ID3 regulate the self-renewal
capacity of human colon cancer-initiating
cells through p21.
Cancer Cell 21, 777,
doi:10.1016/j.ccr.2012.04.036 (2012).
-
Ortmann, J., Rampasek, L., Tai, E. et al.
Assessing therapy response in
patient-derived xenografts.
Sci Transl Med 13, eabf4969,
doi:10.1126/scitranslmed.abf4969 (2021).
-
Pham, N. A., Radulovich, N., Ibrahimov, E. et
al.
Patient-derived tumor xenograft and organoid
models established from resected pancreatic,
duodenal and biliary cancers.
Sci Rep 11, 10619,
doi:10.1038/s41598-021-90049-1 (2021).
-
Prince, E., Cruickshank, J., Ba-Alawi, W. et
al.
Biomimetic hydrogel supports initiation and
growth of patient-derived breast tumor
organoids.
Nat Commun 13, 1466,
doi:10.1038/s41467-022-28788-6 (2022).
-
Rehman, S. K., Haynes, J., Collignon, E. et al.
Colorectal Cancer Cells Enter a
Diapause-like DTP State to Survive
Chemotherapy.
Cell 184, 226,
doi:10.1016/j.cell.2020.11.018 (2021).
-
Ruicci, K. M., Meens, J., Sun, R. X. et al.
A controlled trial of HNSCC patient-derived
xenografts reveals broad efficacy of
PI3Kalpha inhibition in controlling tumor
growth.
Int J Cancer 145, 2100,
doi:10.1002/ijc.32009 (2019).
-
Saraon, P., Snider, J., Kalaidzidis, Y. et al.
A drug discovery platform to identify
compounds that inhibit EGFR triple
mutants.
Nat Chem Biol 16, 577,
doi:10.1038/s41589-020-0484-2 (2020).
-
Saraon, P., Snider, J., Schormann, W. et al.
Chemical Genetics Screen Identifies COPB2
Tool Compounds That Alters ER Stress Response
and Induces RTK Dysregulation in Lung Cancer
Cells.
J Mol Biol 433, 167294,
doi:10.1016/j.jmb.2021.167294 (2021).
-
Shi, R., Varella-Garcia, M., Li, M. et al.
An Anaplastic Lymphoma Kinase
Immunohistochemistry-Negative but
Fluorescence In Situ Hybridization-Positive
Lung Adenocarcinoma Is Resistant to
Crizotinib.
J Thorac Oncol 11, 2248,
doi:10.1016/j.jtho.2016.08.139 (2016).
-
Shi, R., Li, M., Raghavan, V. et al.
Targeting the CDK4/6-Rb Pathway Enhances
Response to PI3K Inhibition in PIK3CA-Mutant
Lung Squamous Cell Carcinoma.
Clin Cancer Res 24, 5990,
doi:10.1158/1078-0432.CCR-18-0717 (2018).
-
Shi, R., Filho, S. N. M., Li, M. et al.
BRAF V600E mutation and MET amplification as
resistance pathways of the second-generation
anaplastic lymphoma kinase (ALK) inhibitor
alectinib in lung cancer.
Lung Cancer 146, 78,
doi:10.1016/j.lungcan.2020.05.018 (2020).
-
Shi, R., Radulovich, N., Ng, C. et al.
Organoid Cultures as Preclinical Models of
Non-Small Cell Lung Cancer.
Clin Cancer Res 26, 1162,
doi:10.1158/1078-0432.CCR-19-1376 (2020).
-
Sinha, A., Hussain, A., Ignatchenko, V. et al.
N-Glycoproteomics of Patient-Derived
Xenografts: A Strategy to Discover
Tumor-Associated Proteins in High-Grade
Serous Ovarian Cancer.
Cell Syst 8, 345,
doi:10.1016/j.cels.2019.03.011 (2019).
-
Stewart, E. L., Mascaux, C., Pham, N. A. et al.
Clinical Utility of Patient-Derived
Xenografts to Determine Biomarkers of
Prognosis and Map Resistance Pathways in
EGFR-Mutant Lung Adenocarcinoma.
J Clin Oncol 33, 2472,
doi:10.1200/JCO.2014.60.1492 (2015).
-
Stewart, J. M., Shaw, P. A., Gedye, C. et al.
Phenotypic heterogeneity and instability of
human ovarian tumor-initiating cells.
Proc Natl Acad Sci U S A 108, 6468,
doi:10.1073/pnas.1005529108 (2011).
-
Tiriac, H., Belleau, P., Engle, D. D. et al.
Organoid Profiling Identifies Common
Responders to Chemotherapy in Pancreatic
Cancer.
Cancer Discov 8, 1112,
doi:10.1158/2159-8290.CD-18-0349 (2018).
-
Wang, D., Pham, N. A., Tong, J. et al.
Molecular heterogeneity of non-small cell
lung carcinoma patient-derived xenografts
closely reflect their primary tumors.
Int J Cancer 140, 662,
doi:10.1002/ijc.30472 (2017).
-
Wang, D., Pham, N. A., Freeman, T. M. et al.
Somatic Alteration Burden Involving
Non-Cancer Genes Predicts Prognosis in
Early-Stage Non-Small Cell Lung
Cancer.
Cancers (Basel) 11,
doi:10.3390/cancers11071009 (2019).
-
Wei, Y., Tong, J., Taylor, P. et al.
Primary tumor xenografts of human lung adeno
and squamous cell carcinoma express distinct
proteomic signatures.
J Proteome Res 10, 161,
doi:10.1021/pr100491e (2011).
-
Wu, L., Allo, G., John, T. et al.
Patient-Derived Xenograft Establishment from
Human Malignant Pleural Mesothelioma.
Clin Cancer Res 23, 1060,
doi:10.1158/1078-0432.CCR-16-0844 (2017).
-
Yoshihito Kano, T. G., Christopher Marshall,
Nikolina Radulovich, Betty Poon, Jonathan
St-Germain, Jonathan Cook, Ivette
Valencia-Sama, Benjamin Grant, Silvia Herrera,
Jinmin Miao, Brian Raught, Meredith Irwin,
Jeffrey Lee, Jen Jen Yeh, Zhong-Yin Zhang,
Ming-Sound Tsao, Mitsuhiko Ikura, and Michael
Ohh.
Tyrosyl phosphorylation of KRAS stalls
GTPase cycle via alteration of Switch I and
II conformation.
Nature Communications (2018).
-
Zhang, W., Wei, Y., Ignatchenko, V. et al.
Proteomic profiles of human lung adeno and
squamous cell carcinoma using super-SILAC and
label-free quantification approaches.
Proteomics 14, 795,
doi:10.1002/pmic.201300382 (2014).